Two Fatalities Associated with Sibutramine

Academic Forensic Pathology

Volumn 2, Issue 4, 2012, Pages 370-373

  Jarvis, Hannah C ^a,b   Gill, James R ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c NONE

Author keywords

Death investigation; Fatality; Forensic pathology; Forensic toxicology; Heart disease; Obesity; Sibutramine

Indexed keywords

EID: 85014537548     PISSN: None     EISSN: 19253621     Source Type: Journal    
DOI: 10.23907/2012.055     Document Type: Article

References (15)

1. Baselt R., Disposition of toxic drugs and chemicals in man. 7th ed. Foster City, (CA): Biomedical Publications; 2004. 1254 p.
2. Arterburn D.E., Crane P.K., Veenstra D.L., The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004 May 10; 164(9): 994–1003.
3. Padwal R.S., Majumdar S.R., Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007 Jan 6; 369(9555): 71–7.
4. Tziomalos K., Krassas G.E., Tzotzas T., The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009; 5(1): 441–52.
5. Harrison-Woolrych M., Ashton J., Herbison P., Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Saf. 2010 Jul 1; 33(7): 605–13.
6. FDA: U.S. Food and Drug Administration [Internet]. Washington: The Administration; c2010. Press release, Abbott Laboratories agrees to withdraw its obesity drug Meridia; 2010 Oct 8 [cited 2012 Nov 26]. Avail able from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm228812.htm.
7. James W.P., Caterson I.D., Coutinho W., Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010 Sep 2; 363(10): 905–17.
8. Muller D., Weinmann W., Hermanns-Clausen M., Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int. 2009 Mar; 106(13): 218–22.
9. FDA: U.S. Food and Drug Administration [Internet]. Washington: The Administration; c2010. Press release, FDA warns consumers not to use Fruta Planta weight loss products; 2010 Dec 31 [cited 2012 Nov 26]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm238491.htm.
10. Gomez-Barrado J.J., Turegano S., Garciperez de Vargas F.J., Porras Y., Acute coronary syndrome in a young woman treated with sibutramine. Rev Esp Cardiol. 2010 Feb; 63(2): 243. English, Spanish.
11. Poss J., Bohm M., Link A., [32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine]. Dtsch Med Wochenschr. 2010 May; 135(19): 965–8. German.
12. Fernandez W.G., Biswas A.K., Myocardial infarction associated with sibutramine use: case report and discussion. Mil Med. 2010 Aug; 175(8): 622–4.
13. Azarisman S.M., Magdi Y.A., Noorfaizan S., Oteh M., Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med. 2007 Nov 1; 357(18): 1873–4.
14. Yim K.M., Ng H.W., Chan C.K., Sibutramine-induced acute myocardial infarction in a young lady. Clin Toxicol (Phila). 2008 Nov; 46(9): 877–9.
15. Wooltorton E., Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ. 2002 May 14; 166(10): 1307–8.